The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest
Alexandre Pichard(Inserm), Jean‐Pierre Pouget(Inserm), Riad Ladjohounlou(Inserm), Alan Courteau(Université Toulouse III - Paul Sabatier), Marta Jarlier(Institut de Recherche en Cancérologie de Montpellier), Guillaume Cartron(Hôpital Saint Eloi), Isabelle Navarro‐Teulon(Inserm), Sebastian Patzke(Norwegian Cancer Society), Vilde Yuli Stenberg(Fafo Foundation), Julie Constanzo(Institut de Recherche en Cancérologie de Montpellier), Helèn Heyerdahl(Nordic Nanovector (Norway)), Manuel Bardiès(Inserm), Peter J. Coopman(Centre National de la Recherche Scientifique), Jostein Dahle(Oslo University Hospital), Ada H. V. Repetto‐Llamazares(Nordic Nanovector (Norway)), Jihad Karam(Inserm), Nathalie Bonnefoy(Inserm), S Marcatili(Université Toulouse III - Paul Sabatier)
Cited by 25
Related Papers
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
|The Lancet|2016|190
DISTRIBUTION OF 5‐AMINOLEVULINIC ACID‐INDUCED PORPHYRINS IN NODULOULCERATIVE BASAL CELL CARCINOMA
|Photochemistry and Photobiology|1995|181